WestHill Financial Advisors Inc. Has $248,000 Position in Johnson & Johnson (NYSE:JNJ)

WestHill Financial Advisors Inc. cut its holdings in Johnson & Johnson (NYSE:JNJ) by 23.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 1,713 shares of the company’s stock after selling 529 shares during the quarter. WestHill Financial Advisors Inc.’s holdings in Johnson & Johnson were worth $248,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of JNJ. IFS Advisors LLC boosted its holdings in shares of Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after buying an additional 100 shares during the period. Highline Wealth Partners LLC bought a new stake in Johnson & Johnson in the 3rd quarter valued at $31,000. Bay Harbor Wealth Management LLC acquired a new position in Johnson & Johnson in the 4th quarter worth $32,000. RPg Family Wealth Advisory LLC bought a new position in Johnson & Johnson during the 3rd quarter worth about $35,000. Finally, Mowery & Schoenfeld Wealth Management LLC raised its stake in shares of Johnson & Johnson by 58.7% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock valued at $40,000 after purchasing an additional 91 shares during the period. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Up 1.7 %

JNJ opened at $162.35 on Friday. The stock’s fifty day simple moving average is $148.93 and its 200 day simple moving average is $155.90. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85. The stock has a market cap of $390.87 billion, a PE ratio of 24.41, a price-to-earnings-growth ratio of 2.53 and a beta of 0.52. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company’s revenue was up 5.3% on a year-over-year basis. During the same period in the prior year, the firm earned $2.29 earnings per share. As a group, research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.06%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s payout ratio is 74.59%.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on JNJ shares. Barclays increased their price objective on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a report on Tuesday, January 28th. Morgan Stanley decreased their price target on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Citigroup cut their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Wells Fargo & Company decreased their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Finally, Raymond James cut their price target on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $170.67.

Insider Transactions at Johnson & Johnson

In related news, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Mark A. Weinberger acquired 1,000 shares of the business’s stock in a transaction on Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.16% of the stock is owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.